VISUAL ABSTRACTWest
By contrast, stable and disrupted plaques showed biomolecule gradients along the sampling length, which implied that substances were being released from plaques into the boundary layer and flowing blood that was coursing over them. Gradients of molecules likely to be derived from the endothelium overlying plaques, especially the oxidized LDL receptor (OLR1; also known as LOX-1) and inflammatory mediators, were detected, consistent with the inflammatory status of endothelium previously defined by ex vivo and postmortem studies.
After angioplasty, some molecular gradients persisted, but release of additional substances was observed, perhaps most interestingly, matrix metalloproteinase-12, which had been localized previously to the core of vulnerable plaques and associated with subsequent unstable presentation.
These experiments establish the feasibility and potential of the Liquid Biopsy System. This new methodology is flexible enough to be used in conjunction with high-content analyses for the definition of prognostic biomarkers or biomarker combinations and for the development of surrogate endpoints in clinical intervention studies aimed at reducing plaque vulnerability and preventing acute coronary syndromes. Statins primarily promote plaque stability by altering biological processes including inflammatory activity of plaques (2), rather than through relatively modest reduction in plaque size (3). Percutaneous catheterbased coronary interventions performed to alleviate angina provide an opportunity to examine the local inflammatory status of plaques by using temperature sensors, ultrasound, light of various wavelengths, and cardiac magnetic resonance (4, 5) . However, of these techniques, only intravascular ultrasonography imaging has yielded prognostic information (6,7), albeit limited, and none of these methods is able to identify whether individual inflammatory mediators or other biomolecules involved in the disease process of atherosclerosis are being actively generated from plaques in vivo.
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We hypothesized that sampling blood to detect gradients of such biomolecules released from obstructive coronary plaques could provide unique information of scientific and, ultimately, clinical utility. Previously, simple micro-catheters have been used to sample coronary artery blood for comparison with venous samples. However, the local gradients thus derived are subject to dilution with blood from other territories, and biomolecules are likely to suffer uptake or biochemical transformation during passage through the coronary microcirculation. Furthermore, as flow through the coronary arteries is predominantly laminar and much more rapid than radial diffusion, biomolecules entering the circulation from the artery wall would most probably become entrained in a nearwall, unstirred boundary layer, inaccessible to conventional catheters placed directly into the coronary arteries. The Liquid Biopsy System (LBS) (PlaqueTec, Ltd., Cambridge, United Kingdom) ( Figure 1A ) was therefore designed specifically to overcome boundary layer effects, thereby allowing more effective blood sampling to identify local gradients of biomolecules in the proximal segment of a target coronary artery, the critical region for culprit plaque formation responsible for most myocardial infarctions (8) .
Following simulations in silico and in vitro and safety testing in a preclinical porcine model, we now report results from the first human safety study and the first human proof of clinical concept evaluation, which were designed to investigate whether the LBS can detect biomolecular gradients in diseased coronary arteries of symptomatic patients undergoing coronary angioplasty and stent deployment. Basic to Translational Science author instructions page.
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West et al. The human proof-of-concept study (NCT02119767) used similar inclusion criteria (n ¼ 23 stable angina pectoris), but in this study, the LBS was positioned within the target artery for planned intervention, and sampling was performed before (when lesion severity and geometry allowed) and after balloon dilation of the plaque. From this study, 1 patient's artery was sampled only before balloon dilation of a target, obstructive, coronary plaque, 11 were sampled before and after balloon dilation, and 15 were sampled only after balloon dilation.
All patients received standard-of-care treatment including dual antiplatelet therapy and periprocedural anticoagulation with heparin; and activated clotting time was maintained at >250 s during LBS sampling. The safety endpoints assessed included West et al.
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RESULTS
The LBS was used to sample blood, including blood from the near-wall, unstirred boundary layers in normal and diseased coronary arteries, as shown schematically in Figure 2A . Because the relationship between NPX and concentration is specific for each analyte, small changes in NPX can represent large-percentage gradients Figure 2C ). For selected analytes, we also show the actual values proximal to, at the midpoint, and distal to the lesions ( Figure 3 , upper row). Details of 9 of the gradients observed after angioplasty are provided in Table 1 (bottom), with data for the same selected analytes expanded in Figure 3 West et al.
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previously. Of the biomolecules showing significant gradients before balloon angioplasty ( CCL2 is a secreted chemokine that is localized to macrophages and SMCs in plaques (19) . On the other Blood sampling across coronary plaques was achieved using the Liquid Biopsy System before balloon dilation and after balloon dilation. Proximal and distal measurements of the biomolecules, identified by their HUGO designations, were used to calculate the change in concentration across plaques, which are shown as median values (range), measured by proximity extension assay multiplex assays and expressed in DNPX units. West et al.
Local Sampling From Atherosclerotic Plaques Instead, we found release of MMP-12 immediately after iatrogenic plaque rupture as part of the angioplasty procedure. MMP-12 is not expressed at detectable levels in human peripheral blood mononuclear cells (25) and may therefore more selectively reflect the status of the plaque.
CONCLUSIONS
Our results demonstrate that gradients of bioactive molecules exist across intact and disrupted atherosclerotic plaques, and these may be sampled and assessed using this novel technology. From the data in TRANSLATIONAL OUTLOOK: The present feasibility studies used 2 relatively small patient cohorts in whom blood was sampled separately from normal coronary arteries or intact plaques before and after disruption by angioplasty. In the future, the Liquid Biopsy System could be used to sample across multiple angiographically significant plaques in the same patient to distinguish vulnerable from stable plaques. Similarly, the panel of biomolecules currently used was simply a small sample from the thousands of disease-related biomolecules that have been identified and for which proximity extension assays could be developed. There is still much to be done to identify the optimal biochemical signature to define a vulnerable plaque. Single biomarkers or combinations will hopefully be defined by future explorations using the device. The sampling technique could also be coupled to high-content "omic" analyses of, for example, proteins or microRNAs. Longitudinal studies could be conducted to investigate the ability of drug interventions to normalize the release of biomolecules, the goal being to define reliable surrogate endpoints for clinical intervention studies. Local Sampling From Atherosclerotic Plaques 653
